TD Cowen analyst Michael Nedelcovych, Ph.D. reiterated a Buy rating on Coherus Biosciences (NASDAQ: CHRS)."We hosted CHRS management at TD ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE